Safety and Effectiveness of an Experimental Drug, IM862, in Treating Kaposi's Sarcoma in AIDS Patients

Launched by CYTRAN · Aug 30, 2001

Keywords

ClinConnect Summary

Patients are stratified by CD4 count, viral load, and prior systemic chemotherapy. Patients are randomized equally to receive either IM862 or placebo given intranasally every other day. Patients are seen every 4 weeks for 6 months or until disease progression to evaluate toxicity and efficacy. Quality of life is assessed before treatment, then every month for 6 months. At the end of the 6-month study evaluation period, patients with PR/CR (responders) remain on study and continue blinded treatment for an additional 6 months. For patients with stable disease (non-responders), the treatment a...

Gender

ALL

Eligibility criteria

• • Inclusion Criteria
• Patients may be eligible for this study if they:
• • Are HIV-positive.
• • Have AIDS-related Kaposi's sarcoma.
• • Have at least 5 skin or mouth sores that do not require chemotherapy.
• • Have been taking anti-HIV drugs for at least 8 weeks before study entry with no changes in the regimen.
• • Are at least 18 years old.
• • Agree to practice effective methods of birth control.
• • Exclusion Criteria
• Patients will not be eligible for this study if they:
• • Have an AIDS-related opportunistic infection (except for genital herpes) within 2 weeks of study entry.
• • Have had another type of cancer within the past 2 years (except for certain types of skin cancer, cervical cancer, or anal cancer).
• • Have a severe chest cold.
• • Have certain other serious medical conditions.
• • Have received certain medications, including chemotherapy, within the past 4 weeks.
• • Abuse alcohol or drugs.
• • Are pregnant or breast-feeding.